Overview
- AbbVie will offer low prices in Medicaid and expand direct-to-consumer sales through the TrumpRx platform for drugs including Humira, Synthroid, Combigan and Alphagan.
- The company disclosed a three-year exemption from tariffs and future pricing mandates as part of the voluntary agreement.
- Combigan and Synthroid are set for Most Favored Nation-level pricing, with reported expectations of additional reductions for Humira and Alphagan.
- Key financial terms and specific discount sizes remain confidential, and analysts question the broader impact on insured patients and Medicaid savings.
- AbbVie becomes roughly the 16th major drugmaker to sign such a pact, following Johnson & Johnson’s recent agreement and ahead of the TrumpRx launch targeted for early 2026.